UCB (CHIX:UCBB) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:UCBB UCB SA CHIX:UCBB
94 GF Score
Price €241.00
GF Value €241.10
Valuation Fairly Valued
View Full Analysis

What is UCB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

UCB Valuation Rank Related Terms

CHIX:UCBB
94GF Score
UCB SA CHIX:UCBB
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UCB (CHIX:UCBB) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be undervalued. The current stock price of €241.00 is trading 0% below its estimated GF Value™ of €241.10. GuruFocus considers UCB to be Fairly Valued.

Key valuation signals for CHIX:UCBB:

  • Valuation Rank:
  • GF Value™: €241.10 vs. price of €241.00 (0% below fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the CHIX:UCBB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
94GF Score

Get the complete analysis for CHIX:UCBB

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€241.00
Price
€241.10
GF Value